01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#POLB Poolbeg Pharma PLC – Combination of Poolbeg and HOOKIPA Pharma Inc. January 2, 2025 – Posted in: Blog

The boards of directors (each a “Board”) of HOOKIPA Pharma Inc. (“HOOKIPA”) and Poolbeg Pharma plc (“Poolbeg”) are pleased to announce that they have entered into non-binding discussions for an all-share acquisition by HOOKIPA of Poolbeg (the “Potential Combination”) to create a strong clinical-stage biopharmaceutical company focused on developing and commercialising innovative medicines for critical unmet medical needs, with a special focus on next-generation immunotherapies for the treatment of cancer and other serious diseases (the…

Continue reading

#ELEG Electric Guitar PLC – 3radical Deploys NFC-Enabled Voco Technology October 9, 2024 – Posted in: Electric Guitar Plc (ELEG)

Electric Guitar PLC (LSE: ELEG), the digital marketing and advertising company providing first-party data solutions, is pleased to announce that its subsidiary, 3radical Limited (“3radical”), has successfully deployed its Voco platform with Near Field Communication (NFC) technology for the first time.   NFC is a technology which enables communication between electronic devices over a distance of four centimetres or less and this innovative solution was showcased at the Grand Designs Live event this month in…

Continue reading

#POLB Poolbeg Pharma PLC – H.C. Wainwright Global Investment Conference August 27, 2024 – Posted in: Poolbeg Pharma (POLB)

27 August 2024 - Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that Jeremy Skillington, PhD, Chief Executive Officer and David Allmond, Chief Business Officer will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference, being held on 9-11 September 2024 in New York and virtually. The presentation will be available to view…

Continue reading

#POLB Poolbeg Pharma PLC – Voluntary Delisting from OTCQB Market July 26, 2024 – Posted in: Poolbeg Pharma (POLB)

26 July 2024- Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it is voluntarily delisting its ordinary shares (“Ordinary Shares”) from trading on the OTCQB Market due to low trading volume and the associated administrative requirements. The Company’s last day of trading on the OTCQB Market will be Monday 29 July 2024. Poolbeg…

Continue reading

#POLB Poolbeg Pharma PLC – Board Role Change and Launch of EIP February 15, 2024 – Posted in: Blog, Poolbeg Pharma (POLB)

15 February 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, “Poolbeg” or the “Company”), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces a change of Board role and the Remuneration Committee’s approval of the adoption of an Employee Performance Incentive Plan (“EIP”) for a number of the key senior management, to align medium and long term objectives with those of shareholders and to encourage…

Continue reading

#POLB Poolbeg Pharma PLC – POLB 001 LPS Trial Data to be Presented at IUIS November 16, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

16 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that an abstract highlighting the potential of POLB 001 as a groundbreaking therapy has been accepted for presentation at the 18th International Congress of Immunology (‘IUIS’), to be held 27 November – 2 December 2023 in Cape Town, South Africa. IUIS is the world’s…

Continue reading